RDIF: Sputnik Light 70% effective against Delta virus strain - Breaking The News

RDIF: Sputnik Light 70% effective against Delta virus strain

13 October

1 min read

EPA-EFE/MOHAMMED SABER

The Gamaleya Research Institute's single-dose vaccine against COVID-19, Sputnik Light, has shown the efficacy of 70% against the Delta variant of the virus, Russian Direct Investment Fund (RDIF) Chief Executive Officer (CEO) Kirill Dmitriev stated on Wednesday.

"The efficacy results of the one-shot Sputnik Light vaccine against the Delta variant of coronavirus significantly outperform those of a number of two-shot vaccines. Crucially, the data from the Gamaleya Center confirms that the one-shot Sputnik Light vaccine is among the best vaccines against coronavirus," Dmitriev said.

Earlier, the RDIF announced Sputnik Light is 93.5% effective against the original strain of COVID-19.

rdif coronavirus coronavirus vaccine sputnik light

Harris slams Trump for 'admiring dictators'

22 October

United States Vice President Kamala Harris, the Democratic presidential nominee, spoke in a recent NBC News interview about the choice Americans face in the upcoming election. She contrasted herself with former President Donald Trump, saying that voters must decide whether they want a leader who she claims openly admires authoritarian figures or not. "The American people are being presented with a choice here about whether we want a president who...

Moderna sued for patent infringement over COVID-19 vaccines

17 October

Northwestern University launched a lawsuit against Modern Inc. in Delaware federal court, accusing it of using the university's innovations to roll out its COVID-19 vaccine, Spikevax, without a license.Northwestern stressed that Moderna completed the first clinical trial of its COVID-19 vaccine a month before the World Health Organization declared the coronavirus outbreak a pandemic, adding that the pharmaceutical company "could not have achieved this...

Moderna gets greenlight for updated COVID jab

3 September

Moderna Inc. shared on Tuesday that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its updated coronavirus vaccine, which targets the JN.1 variant of SARS-CoV-2."COVID-19 continues to present a serious health risk. Updated vaccines targeting circulating strains play a vital role in helping to protect those most at risk from severe illness and hospitalization, alleviating strain on the NHS," Britain's...

FDA greenlights updated Novavax COVID vaccine

30 August

The United States Food and Drug Administration (FDA) approved on Friday the emergency use of the Novavax COVID-19 vaccine for "individuals 12 years of age and older." The approval allows those previously vaccinated to receive one dose, while those who haven't been vaccinated will need two. Similar to the Moderna and Pfizer vaccines, this updated version specifically targets the omicron variant JN.1 of the virus while providing increased protection against...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.